Biomarkers of allograft rejection and tolerance

Choli Hartono, Thangamani Muthukumar, Manikkam Suthanthiran

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter reviews the evolving knowledge regarding biomarkers of kidney allograft rejection and tolerance. The development of noninvasive diagnostic and prognostic biomarkers for allograft rejection and for allograft tolerance is critical to the advancement of transplant medicine. Biomarkers related to the functional attributes of T cells, B cells, and innate cells have shown great promise in predicting transplant outcomes in selected cohorts of patients. Biomarker validation is strengthened by data from large-scale clinical trials. Despite the recent gains from biomarker discovery and validation related to acute T cell-mediated rejection, biomarkers diagnostic of humoral/antibody-mediated rejection remain to be fully defined. Biomarker signature discovery by cross-platform composite efforts from RT-PCR to microarray and flow cytometry may improve the accuracy and predictive values for diagnosing allograft rejection and tolerance. The benchmark of obtaining a serum creatinine measurement is both intuitively and in practice faster than ordering a biomarker test to diagnose allograft dysfunction.

Original languageEnglish
Title of host publicationTransplant Immunology
PublisherWiley Blackwell
Pages259-279
Number of pages21
ISBN (Electronic)9781119072997
ISBN (Print)9780470658215
DOIs
Publication statusPublished - 12 Sep 2015
Externally publishedYes

Fingerprint

Transplantation Tolerance
Biomarkers
Allografts
T-Lymphocytes
Transplants
Benchmarking
Creatinine
Flow Cytometry
B-Lymphocytes
Medicine
Clinical Trials
Kidney
Polymerase Chain Reaction
Antibodies

Keywords

  • Acute T cell-mediated rejection
  • Allograft dysfunction
  • Allograft tolerance
  • Biomarkers
  • Flow cytometry
  • Humoral/antibody-mediated rejection
  • Kidney allograft rejection
  • Microarray
  • RT-PCR

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hartono, C., Muthukumar, T., & Suthanthiran, M. (2015). Biomarkers of allograft rejection and tolerance. In Transplant Immunology (pp. 259-279). Wiley Blackwell. https://doi.org/10.1002/9781119072997.ch13

Biomarkers of allograft rejection and tolerance. / Hartono, Choli; Muthukumar, Thangamani; Suthanthiran, Manikkam.

Transplant Immunology. Wiley Blackwell, 2015. p. 259-279.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hartono, C, Muthukumar, T & Suthanthiran, M 2015, Biomarkers of allograft rejection and tolerance. in Transplant Immunology. Wiley Blackwell, pp. 259-279. https://doi.org/10.1002/9781119072997.ch13
Hartono C, Muthukumar T, Suthanthiran M. Biomarkers of allograft rejection and tolerance. In Transplant Immunology. Wiley Blackwell. 2015. p. 259-279 https://doi.org/10.1002/9781119072997.ch13
Hartono, Choli ; Muthukumar, Thangamani ; Suthanthiran, Manikkam. / Biomarkers of allograft rejection and tolerance. Transplant Immunology. Wiley Blackwell, 2015. pp. 259-279
@inbook{8fff0bd082614a1ab4671cc2653da226,
title = "Biomarkers of allograft rejection and tolerance",
abstract = "This chapter reviews the evolving knowledge regarding biomarkers of kidney allograft rejection and tolerance. The development of noninvasive diagnostic and prognostic biomarkers for allograft rejection and for allograft tolerance is critical to the advancement of transplant medicine. Biomarkers related to the functional attributes of T cells, B cells, and innate cells have shown great promise in predicting transplant outcomes in selected cohorts of patients. Biomarker validation is strengthened by data from large-scale clinical trials. Despite the recent gains from biomarker discovery and validation related to acute T cell-mediated rejection, biomarkers diagnostic of humoral/antibody-mediated rejection remain to be fully defined. Biomarker signature discovery by cross-platform composite efforts from RT-PCR to microarray and flow cytometry may improve the accuracy and predictive values for diagnosing allograft rejection and tolerance. The benchmark of obtaining a serum creatinine measurement is both intuitively and in practice faster than ordering a biomarker test to diagnose allograft dysfunction.",
keywords = "Acute T cell-mediated rejection, Allograft dysfunction, Allograft tolerance, Biomarkers, Flow cytometry, Humoral/antibody-mediated rejection, Kidney allograft rejection, Microarray, RT-PCR",
author = "Choli Hartono and Thangamani Muthukumar and Manikkam Suthanthiran",
year = "2015",
month = "9",
day = "12",
doi = "10.1002/9781119072997.ch13",
language = "English",
isbn = "9780470658215",
pages = "259--279",
booktitle = "Transplant Immunology",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Biomarkers of allograft rejection and tolerance

AU - Hartono, Choli

AU - Muthukumar, Thangamani

AU - Suthanthiran, Manikkam

PY - 2015/9/12

Y1 - 2015/9/12

N2 - This chapter reviews the evolving knowledge regarding biomarkers of kidney allograft rejection and tolerance. The development of noninvasive diagnostic and prognostic biomarkers for allograft rejection and for allograft tolerance is critical to the advancement of transplant medicine. Biomarkers related to the functional attributes of T cells, B cells, and innate cells have shown great promise in predicting transplant outcomes in selected cohorts of patients. Biomarker validation is strengthened by data from large-scale clinical trials. Despite the recent gains from biomarker discovery and validation related to acute T cell-mediated rejection, biomarkers diagnostic of humoral/antibody-mediated rejection remain to be fully defined. Biomarker signature discovery by cross-platform composite efforts from RT-PCR to microarray and flow cytometry may improve the accuracy and predictive values for diagnosing allograft rejection and tolerance. The benchmark of obtaining a serum creatinine measurement is both intuitively and in practice faster than ordering a biomarker test to diagnose allograft dysfunction.

AB - This chapter reviews the evolving knowledge regarding biomarkers of kidney allograft rejection and tolerance. The development of noninvasive diagnostic and prognostic biomarkers for allograft rejection and for allograft tolerance is critical to the advancement of transplant medicine. Biomarkers related to the functional attributes of T cells, B cells, and innate cells have shown great promise in predicting transplant outcomes in selected cohorts of patients. Biomarker validation is strengthened by data from large-scale clinical trials. Despite the recent gains from biomarker discovery and validation related to acute T cell-mediated rejection, biomarkers diagnostic of humoral/antibody-mediated rejection remain to be fully defined. Biomarker signature discovery by cross-platform composite efforts from RT-PCR to microarray and flow cytometry may improve the accuracy and predictive values for diagnosing allograft rejection and tolerance. The benchmark of obtaining a serum creatinine measurement is both intuitively and in practice faster than ordering a biomarker test to diagnose allograft dysfunction.

KW - Acute T cell-mediated rejection

KW - Allograft dysfunction

KW - Allograft tolerance

KW - Biomarkers

KW - Flow cytometry

KW - Humoral/antibody-mediated rejection

KW - Kidney allograft rejection

KW - Microarray

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=84984707533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984707533&partnerID=8YFLogxK

U2 - 10.1002/9781119072997.ch13

DO - 10.1002/9781119072997.ch13

M3 - Chapter

AN - SCOPUS:84984707533

SN - 9780470658215

SP - 259

EP - 279

BT - Transplant Immunology

PB - Wiley Blackwell

ER -